NCT03750227
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Radiation therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have clinical indication for surgical resection of 1 brain metastasis
Exclusions: Patients with leptomeningeal disease or history of WBRT; Patients with greater than 10 brain metastases or any one lesion greater than 5cm
https://clinicaltrials.gov/show/NCT03750227